Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
This trial is aimed to investigate whether additional adjuvant PD-1 antibody treatment could
improve survival in high-risk nasopharyngeal carcinoma compared to metronomic capecitabine
alone.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Affiliated Cancer Hospital of Guizhou Medical University Cancer Hospital of Guangxi Medical University Chongqing University Cancer Hospital Fifth Affiliated Hospital, Sun Yat-Sen University First People's Hospital of Foshan Hubei Cancer Hospital Hunan Cancer Hospital Shandong Provincial Hospital The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Tongji Hospital Wuhan Union Hospital, China Xiangya Hospital of Central South University